Factors influencing serum aluminum in CAPD patients

Clinical Nephrology

Volumn 50, Issue 2, 1998, Pages 77-83

  Montenegro, J ^a   Aguirre, R ^a   Saracho, R ^a   Moina, I ^a   Martinez I ^a  

^a HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Aluminum; CAPD; Duration on CAPD; Iron status; Residual renal function

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; FERRITIN; IRON; PHOSPHATE BINDING AGENT; SERUM ALBUMIN; TRANSFERRIN;

ADULT; AGED; ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED STUDY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; INTESTINE ABSORPTION; IRON STORAGE; KIDNEY DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION;

ALUMINUM; ALUMINUM HYDROXIDE; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; FERRITINS; HUMANS; IRON; KIDNEY; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; TIME FACTORS; TRANSFERRIN;

EID: 0031712516     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Alfrey AC, Higg A, Craswell P 1980 Metabolism and toxicity of aluminum in renal failure. Am J Clin Nut 33: 1509-1516
2. Alfrey AC 1985 The case against aluminum affecting parathyroid function. Am J Kidney Dis 6: 309-312
3. Altmann P, Butter KC, Plowman D, Chaput de Saintonge DM, Cunningham J, Marsh FP 1987 Residual renal function in hemodialysis patients may protect against hyperaluminemia. Kidney Int 32: 110-713
4. Altmann P 1993 Aluminum toxicity in dialysis patients: no evidence for a threshold serum aluminum concentration. Nephrol Dial Transplant 1 (Suppl): 25-34
5. Andreoli SP, Bergstein JM, Sherrard DJ 1984 Aluminum intoxication from aluminum-containing phosphate binders in children with azotemia not undergoing dialysis. N Engl J Med 310: 1079-1084
6. Bakir AA, Hryhorczuk DO, Ahmed S, Hessl SM, Levy PS, Spengler R, Dunea G 1989 Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol 31: 40-44
7. Blaehr H, Madsen S, Rud Andersen J 1986 Effect of iron-loading on intestinal aluminum absorption in chronic renal insufficiency. In: Taylor A (ed). Aluminum and other Trace Elements in Renal Disease. Bailliere Tindall, London, pp 71-75
8. Boelaert JK, Locht M 1993 Side-effects of desferrioxamine in dialysis patients. Nephrol Dial Transplant 1 (Suppl): 43-46
9. Cancarini GC, Brunori G, Camerini C, Brasa S, Maiorca R 1986 Renal function recovery and maintenance of residual diuresis in CAPD and Hemodialysis. Perit Dial Bull 6: 77-79
10. Cannata JB, Diaz López JB 1991 Insights into the complex aluminum and Fe relationship. Nephrol Dial Transplant 6: 605-607
11. Cannata JB, Fernández-Soto I, Fernández-Menénde;. MJ, Fernández-Martín JL, McGregor SJ, Brock JH, Halls D 1991 Role of iron metabolism in absorption and cellular uptake of aluminum. Kidney Int 39: 799-803
12. Cannata JB, Olaizola IR, Gómez-Alonso C, Menéndez-Fraga P, Alonso-Suárez M, Díaz López B 1993 Serum aluminum transport and aluminum uptake in chronic renal failure: role of iron and aluminum metabolism. Nephron 65: 141-146
13. Cheng IKP, Lu HB, Chan CY, Cheng SW, Robinson JD, Tam SC, Lo WK, Cheung WC 1993 The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder. Clin Nephrol 40: 100-105
14. Coburn JW 1993 Mineral metabolism and renal bone disease: Effects of CAPD versus hemodialysis. Kidney Int 40 (Suppl): S 92-S 100
15. Cochran M, Coates JH, Kurusecsev T 1987 Direct spectrophotometric determination of the two site binding of aluminum to transferrin. Life Sci 40: 2337-2341
16. Cochran M, Chantur V, Jones ME, Marshall EA 1991 Iron uptake by human reticulocytes at physiologic and sub-physiologic concentrations of transferrin: The effect of interaction with Al transferrin. Blood 77: 2347-2353
17. De Broe ME, Drüeke TB, Ritz E 1993 Consensus Conference: Diagnosis and Treatment of Aluminum Overload in End-Stage Renal Failure Patients. Nephrol Dial Transplant 1 (Suppl): 1-4
18. 3 increase the intestinal absorption of aluminum. Clin Nephrol 31: 123-127
19. D'Haese PC, Clement JP, Elseviers MM, Lamberts LV, Van de Vyver FL, Visser WJ, De Broe ME 1990 Value of serum aluminum monitoring in dialysis patients: A multicentre study. Nephrol Dial Transplant 5: 45-53
20. Fairweather-Tait SF, Piper Z, Fatemi SJA, Moore GF 1991 The effect of tea on Fe and aluminum metabolism in the rat. Br J Nutr 65: 61-68
21. Hercz G, Salusky IB, Norris KC, Fine RN, Coburn J 1986 Aluminum removal by peritoneal dialysis: Intravenous vs intraperitoneal deferoxamine. Kidney Int 30: 944-948
22. Hodsman AB, Steer BM 1992 Serum aluminum levels as a reflection of renal osteodystrophy status and bone surface aluminum staining. J Am Soc Nephrol 2: 1318-1327
23. Huang JY, Huang Ch, Lin PS, Wu M-S, Leu M-L 1992 Effect of body iron stores on serum aluminum level in hemodialysis patients. Nephron 61: 158-162
24. Hutchison AJ, Were AJ, Boulton HF, Mawer EB, Laing Y, Gokal R 1996 Hypercalcemia, hypermagnesaemia, hyperphosphataemia and hyperaluminaemia in CAPD: improvement in serum biochemistry by reduction in dialysate calcium and magnesium concentrations. Nephron 72: 52-58
25. Ittel TH, Buddington B, Miller NL, Alfrey AC 1987 Enhanced gastrointestinal absorption of aluminum in uremic rats. Kidney Int 32: 821-826
26. Ittel TH, Gladziwa U, Mück W, Sieberth HG 1991 Hyperaluminaemia in critically ill patients: role of antacid therapy and impaired renal function. Eur J Clin Invest 21: 96-102
27. Ittel TH 1993 Determinants of gastrointestinal absorption and distribution of aluminum in health and uraemia. Nephrol Dial Transplant 1 (Suppl): 17-24
28. Kaehny WD, Hegg AP, Alfrey AC 1977 Gastrointestinal absorption of aluminum from aluminum-containing antacids. N Engl J Med 296: 1389-1390
29. Lin J-L, Lim P-S, Leu ML 1995 Relationship of body iron status and serum aluminum in chronic renal insufficiency patients not taking any aluminum-containing drugs. Am J Nephrol 15: 118-122
30. Mactier RA, Nolph KD, Khanna R, Twardowski Z 1986 Risk factors for hyperaluminemia in continuous ambulatory peritoneal dialysis. Perit Dial Bull 6: 188-193
31. Martin RB, Savory J, Brown S, Bertholf RL, Wills MR 1987 Transferrin binding of A13+ and Fe3+. Clin Chem 33: 405-407
32. Mayor GH, Keiser JA, Makdani D, Kn PK 1977 Aluminum absorption and distribution: effect of parathyroid hormone. Science 197: 1187-1189
33. Nestel AW, Meyers AM, Paiker J, Rollin HB 1994 Effect of calcium supplement preparation containing small amounts of citrate on the absorption of aluminum in normal subjects and in renal failure patients. Nephron 68: 197-201
34. Passlick J, Wilhelm M, Busch T, Grabensee B, Ohnesorge FK 1989 Calcium alginate, an aluminum free phosphate binder in patients on CAPD. Clin Nephrol 32: 96-100
35. Pei Y, Hercz G, Greenwood C, Sherrard D, Segre G, Manuel A, Saiphoo C, Fenton S 1992 Non-invasive prediction of aluminum bone disease in hemo-and peritoneal dialysis patients. Kidney Int 41: 1374-1382
36. Rottembourg J, Gallego JL, Jaudon MC, Clavel JP, Legrain M 1984 Serum concentration and peritoneal transfer of aluminum during treatment by continuous ambulatory peritoneal dialysis. Kidney Int 25: 919-924
37. Rottembourg J, Issad B, Gallego JL, Degoulet P, Aine F, Gueffaf B, Legrain M 1983 Evolution of residual renal function in patients undergoing maintenance hemodialysis or continuous ambulatory peritoneal dialysis. Proc EDTA 19: 397-403
38. Salusky IB, Coburn JW, Sherrard DJ, Fine RN 1984 Role of aluminum hydroxide in raising serum aluminum levels in children undergoing CAPD. J Paediatrics 105: 717-720
39. Salusky IB, Foley J, Nelson P, Goodman WG 1991 Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 324: 527-531
40. Slatopolsky E, Weerts C, López-Hilker S, Norwood K, Zink M, Windus D, Delmez J 1986 Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 315: 157-161
41. Trapp GA 1983 Plasma aluminum is bound to transferrin. Life Sci 33: 311-316
42. Van Landeghem GF, D'Haese PC, Lamberts LV, De Broe ME 1997 Competition of iron and aluminum for transferrin: the molecular basis for aluminum deposition in iron-overloaded dialysis patients? Exp Nephrol 5: 239-245
43. Vanuytsel JL, D'Haese PC, Couttenye MM, De Broe ME 1992 Higher serum aluminum concentrations in iron-depleted dialysis patients. Nephrol Dial Transplant 7: 177